Filed with ASX · · 2 pages · English
Mesoblast Limited has reported a significant increase in net revenue and a reduction in operating cash spend for the first fiscal quarter compared to the previous year period, highlighting its strong financial position. The Chief Executive emphasized plans for continued growth and disciplined capital allocation to maximize shareholder value.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings Call
MESOBLAST REPORTS 44% INCREASE IN RYONCIL® NET REVENUE AND 85% IMPROVEMENT IN NET OPERATING CASH SPEND IN FIRST FISCAL QUARTER OVER PRIOR YEAR PERIOD New York, USA: October 15 and Melbourne, Australia: October 16, 2026: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular...
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast